BRIEF-ProMetic announces the addition of tympanic membrane perforations to its plasminogen's targeted indications
Sept 6 (Reuters) - ProMetic Life Sciences Inc
* Will be pursuing tympanic membrane perforations as one of its new plasma-derived plasminogen targeted clinical indications
* Expects to file its clinical trial application in Q4 2016
* Expects to initiate clinical trial in Sweden in patients suffering from chronic tympanic membrane perforations in H1 2017 Source text for Eikon: Further company coverage:
© Thomson Reuters 2017 All rights reserved.